

Benaroya Research Institute
IBC MEETING AGENDA
Thursday JANUARY 29, 2026
11:00 AM - 01:00 PM
4 North Conference Room / Zoom

Commonly Used Abbreviations

IBC: Institutional Biosafety Committee
BSO: Biological Safety Officer
BSL: Biosafety Level
PI: Principal Investigator
IACUC: Institutional Animal Care and Use Committee
NIH: National Institutes of Health
RPD: Research Protections Department
BRI: Benaroya Research Institute
BSC: Biosafety Cabinet
SOP: Standard Operating Procedure

VOTING MEMBERS PRESENT:	Adam Lacy-Hulbert, PhD (<i>IBC Chair, Animal Containment Expert</i>) Vivian Gersuk, PhD (<i>IBC Vice Chair</i>) Estelle Bettelli, PhD (<i>Animal Containment Expert</i>) Bernard Khor, MD, PhD (<i>Affiliated Physician</i>) Alison Cushman (<i>Community Member</i>) Andrew Burich, DVM (<i>Animal Containment Expert</i>) Alice Wiedeman, PhD (<i>Affiliated Member</i>) John Ray, PhD (<i>Affiliated Member</i>) Shared seat: Angela Webb, RN (<i>Affiliated Member</i>)
ALTERNATE VOTING MEMBER(S) PRESENT:	None
VOTING MEMBERS ABSENT:	Uma Malhotra, MD (<i>Affiliated Physician</i>) Shared seat: Nadell Knee, MSN (<i>Affiliated Member</i>) Ken Gordon (<i>Community Member</i>)
ADMINISTRATIVE SUPPORT:	Tessa Woods
OTHERS PRESENT:	Cheryl Weaver, BA, CCRC, CCRA Sarah Valenti, JD, CIP Vijaya Valiveti Annthea Vining Amir Figueroa, PhD

*As of this meeting, the BRI IBC board has 12 active voting members, with one shared seat (11 seats total).
To achieve quorum, at least 6 members are required to be present for voting (including experts as necessary).*

1. Call to Order by the IBC Chair and Introduction of Guests

For the purposes of voting today, Members were instructed that after each proposal in favor of passing to verbally confirm if in favor, by stating “aye.” Any member abstaining or voting against the proposal should identify himself or herself so the vote count can be accurate. The Chair will not check votes member by member, and if no abstentions or votes against a proposal are taken, the proposal will be assumed to have passed unanimously.

The IBC administrator took roll by recording the names of all attendees.

2. Confidentiality of Panel Proceedings

The members of the Benaroya IBC and the persons employed by the IBC were asked to maintain the confidentiality of the committee's proceedings unless such information was already made available to the public. The Parties shall maintain the confidentiality of the IBC's hearings, deliberations and initial report, and all written submissions to, and communications with, the IBC.

3. Conflict of Interest Notice

The Chair reminded committee members of Virginia Mason Health Systems policies regarding conflict of interest and asked that any member who might have a conflict of interest make it known and abstain from the vote.

4. Review of Draft Minutes from the Previous Meeting

A. November 20, 2026 IBC Meeting Minutes

IBC Decision and Vote				
A motion was made to approve the meeting minutes after the modifications mentioned in the meeting are met. The motion was seconded.				
For: 9	Against: 0	Abstained: 0	Absent: 2	Recused: 0

5. Safety Update

The board discussed highlights of the Annual Safety Review. There were a few biohazard safety containers that were almost full. We found some maintenance issues, missing labels on fridges, and other maintenance issues that were found. We’re still figuring out who can help us with this, but there should be an update. Otherwise, everything looked good. No clear evidence

Injury Exposure Report

6. Notification of Administrative Action (11/08/25 – 01/15/25)

A. Protocol ID: IBC23-007, Amendment

PI	Title	BSL	NIH Guidelines
Lin, Bruce	A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus	2	III-C, III-D, III-E

	watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection		
Additional Safety Practices:	n/a		
Primary Reviewer:	Lacy-Hulbert, Adam		
Summary:	Updated sponsor IB submitted. Biosafety training is up to date. Treatment cards and information sheets are available to staff.		
Approved on: 11/14/25			

7. New Business

A. Protocol ID: IBC25-037, Three-year Renewal

PI	Title	BSL	NIH Guidelines
Bettelli, Estelle	Cooperation between adaptive and innate immune responses in autoimmunity	1, 2	III-D, III-E
Additional Safety Practices:	n/a		
Recused:	Bettelli, Estelle		
Primary Reviewer(s):	Khor, Bernard; Ray, John		
Discussion:	<p><i>The Principal Investigator</i> provided the IBC with an overview of the protocol, its design, and its aims. The Application included additional biohazards and their proposed containment levels.</p> <ul style="list-style-type: none"> The Committee reviewed the application, conducted a risk assessment, and determined the biocontainment levels for the research proposed met all applicable NIH Guidelines. The Committee confirmed the facilities, procedures, practices, training and expertise of personnel are adequate for safe work with all biohazards listed. <ul style="list-style-type: none"> Biosafety training is up to date for all staff <p>Treatment cards and information sheets are available to staff.</p> <p><i>Estelle Bettelli left the meeting due to her conflict of interest.</i></p>		
Decision:	<p>The IBC discussed the criteria for approval and required the following modifications:</p> <ol style="list-style-type: none"> Minor revisions to the application as outlined in eProtocol comments and per discussion. 		

IBC Decision and Vote				
A motion was made to approve the protocol after the modifications mentioned in the meeting and in eProtocol are met. The motion was seconded.				
For: 8	Against: 0	Abstained: 0	Absent: 2	Recused: 1

Estelle Bettelli returned to the meeting.

B. Protocol ID: IBC25-035, Three-year Renewal

PI	Title	BSL	NIH Guidelines
Nguyen, Thien-Son	BRI Repository	1, 2	n/a
Additional Safety Practices:	n/a		
Recused:	n/a		
Primary Reviewer(s):	Wiedeman, Alice; Gersuk, Vivian		
Discussion:	<p>The primary reviewers provided the IBC with an overview of the protocol, its design, and its aims. The Application included additional biohazards and their proposed containment levels.</p> <ul style="list-style-type: none"> The Committee reviewed the application, conducted a risk assessment, and determined the biocontainment levels for the research proposed met all applicable NIH Guidelines. The Committee confirmed the facilities, procedures, practices, training and expertise of personnel are adequate for safe work with all biohazards listed. <ul style="list-style-type: none"> Biosafety training is up to date for all staff Treatment cards and information sheets are available to staff. 		
Decision:	<p>The IBC discussed the criteria for approval and required the following modifications:</p> <ol style="list-style-type: none"> Minor revisions to the application as outlined in eProtocol comments and per discussion. 		

IBC Decision and Vote				
A motion was made to approve the protocol after the modifications mentioned in the meeting and in eProtocol are met. The motion was seconded.				
For: 9	Against: 0	Abstained: 0	Absent: 2	Recused: 0

C. Protocol ID: IBC26-001, Vote to Extend Expiration of Protocol

PI	Title	BSL	NIH Guidelines
Ziegler, Steven	Regulation of Immunity and Inflammation	1, 2	III-D, III-E
Additional Safety Practices:	n/a		
Recused:	n/a		
Primary Reviewer(s):	n/a		
Discussion:	The board discussed the possibility of closing this protocol due to upcoming staffing changes. Relevant study personnel will be transferred to other protocols as appropriate.		
Decision:	The IBC discussed granting the protocol an extension to April 1, 2026. Safety will discuss disposal of biohazards with the lab.		

IBC Decision and Vote				
A motion was made to approve granting the protocol an extension to April 1, 2026. The motion was seconded.				
For: 9	Against: 0	Abstained: 0	Absent: 2	Recused: 0

8. Discussion Items

n/a

9. Adjournment

Next meeting March 26, 2026, 11:00am, 4 North Conference Room / Zoom



box SIGN 31RJ7/L1W-4YKZ5X58Adam Lacy-Hulbert, PhD
IBC ChairMay 6, 2026

Date

Prepared by:



box SIGN 21XY6L4Y-4YKZ5X58Tessa Woods
Regulatory Specialist IIApr 14, 2026

Date

ecc: Jane Buckner, MD, BRI President
Margaret McCormick, PhD, BRI Institutional Official
Cheryl Weaver, BA, CCRC, CCRA, Director of Research Integrity & Safety
Adam Lacy-Hulbert, PhD, IBC Chair
IBC Office File